Immunic (NASDAQ:IMUX) Earns Buy Rating from HC Wainwright

Immunic (NASDAQ:IMUX)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a report issued on Friday,Benzinga reports. They currently have a $10.00 price target on the stock.

Several other research firms also recently issued reports on IMUX. StockNews.com downgraded shares of Immunic from a “hold” rating to a “sell” rating in a research note on Monday, February 10th. D. Boral Capital reaffirmed a “buy” rating and set a $17.00 price objective on shares of Immunic in a research report on Thursday. One analyst has rated the stock with a sell rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $12.67.

Immunic Trading Up 6.6 %

NASDAQ:IMUX opened at $1.26 on Friday. The firm has a market capitalization of $113.32 million, a price-to-earnings ratio of -1.02 and a beta of 1.87. The firm’s fifty day simple moving average is $1.02 and its 200 day simple moving average is $1.26. Immunic has a twelve month low of $0.92 and a twelve month high of $2.11.

Institutional Trading of Immunic

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Focus Partners Wealth raised its holdings in shares of Immunic by 1.1% in the 4th quarter. Focus Partners Wealth now owns 2,168,353 shares of the company’s stock worth $2,168,000 after purchasing an additional 23,610 shares in the last quarter. 683 Capital Management LLC raised its holdings in shares of Immunic by 2.2% during the fourth quarter. 683 Capital Management LLC now owns 700,000 shares of the company’s stock valued at $700,000 after acquiring an additional 15,349 shares during the period. Millennium Management LLC raised its holdings in shares of Immunic by 480.6% during the fourth quarter. Millennium Management LLC now owns 579,683 shares of the company’s stock valued at $580,000 after acquiring an additional 479,846 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Immunic by 45.6% during the fourth quarter. Renaissance Technologies LLC now owns 566,623 shares of the company’s stock valued at $567,000 after acquiring an additional 177,542 shares during the period. Finally, Bridgeway Capital Management LLC raised its holdings in shares of Immunic by 11.5% during the fourth quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company’s stock valued at $215,000 after acquiring an additional 22,200 shares during the period. 51.82% of the stock is currently owned by institutional investors.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.